Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Feeley

Plastic Surgery within the Head & Neck Nashville, TN Medical Doctor

NPI 1598773939 CMS profile 345063

3601 The Vanderbilt Clinic, Nashville, TN 37232

Open in the dashboard

General payments

$2,512

56 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Feeley of Nashville, TN is reported in the CMS Open Payments database as having received $2,512 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $298 10
2024 General $808 5
2023 General $381 6
2022 General $232 11
2021 General $207 9
2020 General $48 3
2019 General $538 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Feeley
  • Plastic Surgery within the Head & Neck median
  • Middle half of Plastic Surgery within the Head & Neck
  • National median

In program year 2025, general payments to Marc Feeley were reported at $298. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.

Show as a table
Year Marc Feeley Plastic Surgery within the Head & Neck median Middle half National median
2019 $538 $200 $82–$550 $163
2020 $48 $120 $46–$330 $114
2021 $207 $166 $60–$382 $132
2022 $232 $208 $83–$530 $149
2023 $381 $202 $77–$538 $160
2024 $808 $260 $99–$645 $164
2025 $298 $237 $103–$520 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,052 19 payments
  2. Medtronic, Inc. $325 6 payments
  3. Olympus Corporation of the Americas $324 2 payments
  4. Intersect ENT, Inc. $143 3 payments
  5. ALK-Abello, Inc $139 1 payment
  6. Regeneron Healthcare Solutions, Inc. $131 7 payments
  7. GlaxoSmithKline, LLC. $131 7 payments
  8. Acclarent, Inc $85 4 payments
  9. Genzyme Corporation $75 3 payments
  10. Sanofi-Aventis U.S. LLC $57 1 payment
  11. Other $49 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,171 41 payments
  2. Travel and Lodging $767 7 payments
  3. Consulting Fee $320 6 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $197 1 payment
  5. Education $57 1 payment
Products named General payments · program years 2019–2025
  1. SCOPIS ENT $643 9 payments
  2. DUPIXENT Immunology $202 7 payments
  3. Gyrus ACMI $197 1 payment
  4. CLARIFIX CRYOTHERAPY DEVICE $176 2 payments
  5. PROPEL Otolaryngology (Ear, Nose, Throat) $155 2 payments
  6. PROPEL Otolaryngology (Ear, Nose, Throat) $143 3 payments
  7. Odactra $139 1 payment
  8. DUPIXENT Inflammation And Immunology $131 7 payments
  9. NUCALA $131 7 payments
  10. Celon System $127 1 payment
  11. Other $883 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

929

Median for Otolaryngology: 297

Drug cost

$20,584

Median for Otolaryngology: $6,314

Branded share of claims

18%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 189 $5,383
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 29 $3,045
Fluticasone Propionate Generic 124 $1,862
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 80 $1,820
Fluocinolone Acetonide Oil Generic 38 $1,449
Omeprazole Generic 70 $1,063
Ipratropium Bromide Generic 34 $1,053
Cefuroxime Cefuroxime Axetil Brand 30 $976
Ofloxacin Generic 57 $885
Methylprednisolone Generic 95 $695

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$83,005

Medicare's payments for the services billed

Medicare patients

443

Average age 74

Services billed

1,193

234 women, 209 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 32%
Diabetes 29%
Depression 29%
Chronic kidney disease 24%
COPD 19%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery within the Head & Neck in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record